Cargando…

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression

In preclinical models, c-Met promotes survival of renal cancer cells through the regulation of programmed death-ligand 1 (PD-L1). However, this relationship in human clear cell renal cell carcinoma (ccRCC) is not well characterized. We evaluated c-Met expression in ccRCC patients using paired primar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lalani, Aly-Khan A., Gray, Kathryn P., Albiges, Laurence, Callea, Marcella, Pignon, Jean-Christophe, Pal, Soumitro, Gupta, Mamta, Bhatt, Rupal S., McDermott, David F., Atkins, Michael B., Woude, G.F. Vande, Harshman, Lauren C., Choueiri, Toni K., Signoretti, Sabina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732739/ https://www.ncbi.nlm.nih.gov/pubmed/29262573 http://dx.doi.org/10.18632/oncotarget.21952

Ejemplares similares

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1
por: Chakraborty, Samik, et al.
Publicado: (2019)

Regulation of HHLA2 expression in kidney cancer and myeloid cells
por: Shigemura, Tomonari, et al.
Publicado: (2023)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
por: Choueiri, Toni K., et al.
Publicado: (2020)

Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
por: Tripathi, Abhishek, et al.
Publicado: (2020)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection
por: Sakamoto, Naoko, et al.
Publicado: (2017)

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
por: Zhang, Liang, et al.
Publicado: (2011)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
por: Fay, André P, et al.
Publicado: (2015)

In Reply
por: de Velasco, Guillermo, et al.
Publicado: (2017)

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2011)

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016)

Landscape of tumor-infiltrating T cell repertoire of human cancers
por: Li, Bo, et al.
Publicado: (2016)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Li, Haoxin, et al.
Publicado: (2019)

Germline Met Mutations in Mice Reveal Mutation- and Background-Associated Differences in Tumor Profiles
por: Graveel, Carrie R., et al.
Publicado: (2010)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Circulating KIM-1 is a minimally invasive biomarker correlated with treatment response to nivolumab in patients with metastatic renal cell carcinoma
por: Xu, Wenxin, et al.
Publicado: (2023)

A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape
por: Sabarwal, Akash, et al.
Publicado: (2020)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth
por: Balan, Murugabaskar, et al.
Publicado: (2017)

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma
por: de Velasco, Guillermo, et al.
Publicado: (2018)

A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress
por: Rawat, Laxminarayan, et al.
Publicado: (2023)

Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate
por: Pignon, Jean-Christophe, et al.
Publicado: (2015)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
por: Song, Kyu Young, et al.
Publicado: (2020)

Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma
por: Saliby, Renee Maria, et al.
Publicado: (2023)

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward
por: Harshman, L.C., et al.
Publicado: (2017)

PD-1 as a potential target in cancer therapy
por: McDermott, David F, et al.
Publicado: (2013)

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2018)

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma
por: Johnson, Jennifer, et al.
Publicado: (2015)

MET expression during prostate cancer progression
por: Verhoef, Esther I., et al.
Publicado: (2016)

Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation
por: Zhang, Yu-Wen, et al.
Publicado: (2012)

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
por: Lalani, Aly-Khan A., et al.
Publicado: (2018)

A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model
por: Hu, Junhui, et al.
Publicado: (2018)

Expression of c-MET in Invasive Meningioma
por: Yun, Sumi, et al.
Publicado: (2015)

Management of metastatic renal cell carcinoma in patients with poor prognosis
por: Bullock, Andrea, et al.
Publicado: (2010)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
por: Rini, Brian I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_98qmgejrbnnm91n26t2b9hogmu